LP
GALT icon

LMR Partners’s Galectin Therapeutics GALT Stock Holding History

LMR Partners’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-19,285
Closed -$62K – 1070
2021
Q2 		$62K Buy
+19,285
New +$68.6K ﹤0.01% 956
2015
Q3 		– Sell
-10,099
Closed -$27K – 377
2015
Q2 		$27K Buy
+10,099
New +$30.4K ﹤0.01% 508

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

LMR Partners's GALT Position: Q3 2021 in Review

LMR Partners sold out of Galectin Therapeutics (GALT) in Q3 2021, closing a stake of 19,285 shares — an estimated $62K sold.

LMR Partners first reported a position in GALT in Q2 2015 and held it in 2 quarters. The position peaked at $62K in Q2 2021. 70 funds tracked by Wall St. Rank hold GALT as of Q3 2021.

  • LMR Partners reported no remaining Galectin Therapeutics position as of Q3 2021 after selling out during the quarter.
  • LMR Partners sold 19,285 Galectin Therapeutics shares in Q3 2021, an estimated $62K.
  • LMR Partners first reported a position in Galectin Therapeutics in Q2 2015 and held it in 2 quarters.
  • LMR Partners's Galectin Therapeutics position peaked at $62K in Q2 2021.
  • 70 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.